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Background: Ductal carcinomas of the parotid gland are rare, highly aggressive, have a poor prognosis and are
histologically similar to Ductal Breast Cancer. We report what we believe to be the first case in literature of
metastatic salivary duct carcinoma (SDC) of the parotid gland with objective response to tamoxifen and aromatase
inhibitors, achieving a long-term stability of disease with no associated toxicity.
Case presentation: A 70-year-old female was referred to our institution for treatment of a painless nodular lesion
in the scalp, localized in the frontal region of the cranium. A biopsy was taken and tested positive for metastatic
ductal carcinoma. On PET CT hypermetabolic nodules were localized in the left parotid gland (11 mm), right parotid
gland (10 and 12 mm), submandibular node (11 mm) and left cervical node (10 mm). A salivary ductal carcinoma
was considered to be the primary tumor. The patient was subsequently started on tamoxifen, with a complete
response from the scalp nodule and left parotid nodule, while the right parotid nodule demonstrated a partial
response that maintained stable for 2 years until progression. Anastrazol was chosen as the next line of treatment,
achieving 6 more months of stable disease. As a pseudo-adjuvant treatment, surgical resection of the right parotid
lesion was performed and helped achieve two years of disease stability.
Conclusions: Estrogen receptor antagonists such as tamoxifen or aromatase inhibitors may represent a target for
the establishment of a safe alternative and novel therapy for SDC, however more accurate data obtained from
larger studies are required.
Keywords: Tamoxifen, Salivary gland, Ductal carcinoma, Estrogen receptor antagonistBackground
Ductal carcinomas of the parotid gland are rare, highly
aggressive, have a poor prognosis and are histologically
similar to Ductal Breast Cancer. Salivary gland tumors
metastasize most frequently to lymph nodes, lung, liver
and bones. Distant metastases occur in 27%, independ-
ent of histology and 46% in adenoid cyst cell types and
high-grade salivary ductal carcinoma [1]. Surgical resec-
tion of solitary metastasis may be considered in select
cases, but the goal of chemotherapy in metastatic or
recurrent disease is palliative care, based on response* Correspondence: saulcampos@gmail.com
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article, unless otherwise stated.rates that range from 10-30% and the lack of evidence
benefiting survival [2].
Salivary ductal carcinomas are an uncommon and
high-grade adenocarcinoma arising from the ductal
epithelium, which Kleinsasser et al. reported in 1968 for
the first time [3], and the World Health Organization
classified as a distinct neoplasm in 1991 [4]. Ductal
carcinomas, typically present in the sixth or seventh
decade of life and are more prevalent in males (3:1.8)
[5,6]. The parotid gland is involved in 80% of diagnosis,
followed by the submandibular gland in 8% and the rest
in the minor salivary glands [7,8]. The aggressive beha-
vior characterizing ductal carcinomas is associated with
rapid progression, early lymph node metastasis, a high
risk of local recurrence, distant metastasis and ultimately
a low survival rate, 3 yrs. median [9,10].
Due to SDC’s histological similarity to ductal carcinoma
of the breast, hormonal receptor status and regulation hasCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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expression is virtually absent in most malignant salivary
gland tumors, with the exception of the androgen re-
ceptor, which is present in approximately 92% of cases.
Similar to invasive ductal carcinoma of the breast, over-
expression and amplification of the HER-2 gene is
present in SDC. Patients with SDC and HER-2 over-
expression and amplification may be targeted with tras-
tuzumab and obtain positive responses to therapy [8].
SDC in comparison to ductal carcinoma of the breast
expresses in a lower percentage estrogen (−8%) or
progesterone receptors [9]. Androgen receptor (AR)
therapy however has emerged as a possible target, due
to the fact that a majority of SDC lesions express AR
and have demonstrated clinical benefit [10].
Cytotoxic chemotherapy has limited benefit in a sub-
type of SDC that is rare and aggressive, for which geno-
typing analysis has been pursued to help identify novel
tumor-specific mutations that may help direct targeted
therapies in these cases. There has been an interest in
recently discovered PIK3CA, PTEN and BRAF V600E
kinase mutations in subsets of HER2-negative SDC; due
to these recent discoveries the aforementioned pathways
have been suggested as therapeutic targets [11,12].
The following case report is what we believe to be the
first case in literature of metastatic salivary duct carcin-
oma of the parotid gland with objective response to tam-
oxifen and aromatase inhibitors, achieving a long-term
stability of disease with no associated toxicity.
Case presentation
A 70-year-old female was referred for treatment of a
painless nodular lesion with a diameter of 2 cm in the
scalp, localized in the frontal region of the cranium. Her
past medical history was unremarkable. A biopsy was
taken and tested positive for metastatic ductal carci-
noma. Further analysis revealed Estrogen Receptor posi-
tivity. Mastrography and CT did not demonstrate any
evidence of a primary tumor, while PET CT showed
hypermetabolic nodules localized as follows: 11 mm in
the left parotid gland, 10 and 12 mm in the right parotid
gland, 11 mm submandibular node and 10 mm left
cervical node. At this point, there was clinical suspicion
of a primary salivary ductal carcinoma. The patient
was started on tamoxifen, 20 mg daily, with a complete
response in the scalp nodule and left parotid nodule,
although a partial response was observed on the right
parotid lesions (Figure 1B). The patient continued
stable for two years, after which progression of the
right parotid nodule was observed through clinical
palpation and through CT as a lesion 2 cms in diam-
eter located in the right periaricular area (Figure 1C),
without cranial nerve involvement or palpable cervical
lymphadenopathy. There was no evidence of any metastaticlesions. Anastrozole 1 mg/day was started, achieving stable
disease within 8 months of treatment (Figure 1D).
Local control of the parotid lesion was obtained via
surgical resection (Figure 1E), tissue was sent to path-
ology, where a Hematoxylin and Eosin (H & E) stained
section showed ductal structures (Figure 2A). Immu-
nohistochemistry was performed using standard proce-
dures with monoclonal antibodies: 6 F11 (Novacastra
Laboratories Ltd., Burlingame, CA) for ER and 1A6
(Novacastra Laboratories Ltd., Burlingame) for PR and
AB-8 monoclonal antibody (NeoMarker Lab Vision
Co., Fremont, CA) for Her2, which proved negative for
Her2neu and positive for Estrogen and Progesterone
Receptors (Figure 2B, C, D). The tumor was classified
as a salivary duct carcinoma of the parotid gland. At
this time, the patient had been receiving anastrozole as
pseudo adjuvancy for two years without further evi-
dence of disease (Figure 1F).
Conclusions
The histologic similarities between salivary duct carcin-
oma and ductal carcinoma of the breast in addition to the
low response rates to chemotherapy have led to antihor-
monal therapies being considered for treatment. Salivary
duct carcinomas responding to antiandrogen therapies
and advanced adenoid cystic salivary tumors to Tamoxifen
have been reported in the literature [13,14]. However,
Tamoxifen and Aromatase inhibitors (estrogen signaling
inhibitor agents) have not been reported in the literature,
due to the low expression of ER in Ductal Carcinoma of
the Salivary Gland.
Tamoxifen and anastrazole have proven to be effective
in Ductal Carcinoma of the Breast and were considered a
potential novel therapy in this case, stopping the progres-
sion of salivary gland carcinoma (SGC) and achieving
long-term stability of ductal parotid carcinoma. Tamoxifen
prevents the activation of estrogen responsive genes by
inhibiting both translocation and nuclear binding of the
receptor itself. Aromatase inhibitors like Anastrozole on
the other hand prevent ER activation by inhibiting the
conversion of androgens to estrogens by binding to the
aromatase enzyme.
Due to limited management options in salivary gland
carcinoma and low rates of response to chemotherapy
the goal of treatment for metastatic salivary gland car-
cinoma is palliation, since there is not strong evidence
that survival is prolonged with systemic treatment. Tar-
geted cancer therapies represent a promising strategy to
treat these rare aggressive malignancies. Albeit, the ex-
pression of sex steroid hormone receptors in salivary
gland carcinoma and the evidence of linking hormone
receptors and growth factor receptors to the disease
may lead to the use of hormone therapy in these spe-
cific cases. Estrogen receptor antagonists such as
Figure 1 Computed Tomography (CT). A CT showing solid lesion in right parotid gland (Baseline), B Stable Disease under tamoxifen treatment.
C Growth of the solid lesion in right parotid, D Stable Disease after switch to anastrazol, E Postsurgical CT showing absence of right parotid gland
F Stable disease in surveillance.
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get for the establishment of a safe alternative therapy
for SDC but more accurate data obtained from larger
studies are required.
Genetic profiling is a valuable approach to identify ac-
tionable mutations (BRAF or PIK3CA mutations) whichFigure 2 Haematoxylin-eosin stain (H & E) and Immunohistochemical
growth pattern (H & E), B. Her2/neu immunostaining showing negative me
Progesterone receptor immunostain.could have a significant impact in this rare in highly ag-
gressive malignancy.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanyingstudies. A Salivary Duct Carcinoma of Parotid Gland with cribriform
mbrane staining, C Positive Estrogen receptor immunostain, D Positive
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